Compare FTHM & CCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FTHM | CCEL |
|---|---|---|
| Founded | 2010 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Managed Health Care |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.8M | 30.9M |
| IPO Year | 2020 | 2022 |
| Metric | FTHM | CCEL |
|---|---|---|
| Price | $0.86 | $3.63 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 1 |
| Target Price | ★ $2.50 | N/A |
| AVG Volume (30 Days) | ★ 296.1K | 11.9K |
| Earning Date | 05-12-2026 | 04-14-2026 |
| Dividend Yield | N/A | ★ 4.26% |
| EPS Growth | ★ 32.71 | N/A |
| EPS | N/A | ★ 0.07 |
| Revenue | ★ $420,477,000.00 | $25,384,279.00 |
| Revenue This Year | $11.67 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $50.00 |
| Revenue Growth | ★ 25.45 | 9.76 |
| 52 Week Low | $0.40 | $2.72 |
| 52 Week High | $3.37 | $5.43 |
| Indicator | FTHM | CCEL |
|---|---|---|
| Relative Strength Index (RSI) | 47.35 | 50.02 |
| Support Level | $0.85 | $3.00 |
| Resistance Level | $1.07 | $3.64 |
| Average True Range (ATR) | 0.06 | 0.24 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 26.84 | 41.29 |
Fathom Holdings Inc is a national, technology-driven, real estate services platform integrating residential brokerage, mortgage, title, and Software as a Service (SaaS) offerings to brokerages and agents by leveraging intelliAgent , proprietary cloud-based software. The Company's three operating and reportable segments: Real Estate Brokerage, Mortgage, and Title. The majority of revenue is from Real Estate Brokerage, which provides real estate brokerage services.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.